|
KMID : 1146920180480050527
|
|
Journal of Pharmaceutical Investigation
2018 Volume.48 No. 5 p.527 ~ p.539
|
|
|
Nano delivery systems and cancer immunotherapy
|
|
Le Quoc-Viet
Choi Jin-Joo
Oh Yu-Kyoung
|
|
|
Abstract
|
|
|
|
Cancer immunotherapy takes advantage of immune system to fight against cancer. Current clinical immunotherapies are based on the administration of immune checkpoint inhibitors or immune modulators to reverse the immune suppression. Although robust and long-term tumor suppression is induced in “certain treated population”, single immunotherapy still suffers from limited efficacy in clinic. Combination with nanomedicine would be one of major strategies that can widen the effective patient populations and reduce side effects. The basis in combining nanomedicine and immunotherapy stems from the close relationship of tumor and immune system. Depending on the therapeutic cargo, nanocarriers can not only facilitate stronger innate or adaptive immunity but also reverse of immunosuppression. In the other hand, nanotechnology can potentiate the efficacy of immunotherapy by enhancing the delivery, retention and narrow the toxicity of immunomodulators. The strategies and rationales of nanocarrier design in the context of cancer immunotherapy are discussed in this review.
|
|
|
KEYWORD
|
|
|
Nanomedicine, Immunotherapy, Immune checkpoint inhibitor, Cancer, Combination
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|